

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

AMERICAN PHARMACISTS ASSN

2. Address:

1100 15TH STREET, NW, SUITE 400, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country): HOLLAND

4. Contact Name: KRISTINA LUNNER

Telephone: 202-429-7507

E-mail (optional): klunner@aphanet.org

Senate ID #: 3071-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 127,143.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.CON.RES. 376: Establishing the congressional budget for the United States Government for fiscal year 2007 and setting forth appropriate budgetary levels for fiscal years 2008 through 2011; Student Financial Aid. S.CON.RES. 83: Setting forth the congressional budget for the United States Government for fiscal year 2007 and including the appropriate budgetary levels for fiscal years 2006 and 2008 through 2011; Student Financial Aid. H.R. 3660: District of Columbia Appropriations Act, 2007.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BISHOP, SUSAN K
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A
Name: WINCKLER, SUSAN C.
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Emergency Preparedness & Response. H.R. 1020: National Pain Care Policy Act of 2005.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BISHOP, SUSAN K

Covered Official Position (if applicable): N/A

Name: JAMGOCHIAN, HRANT

Covered Official Position (if applicable): N/A

Name: LUNNER, KRISTINA E.

Covered Official Position (if applicable): N/A

Name: WINCKLER, SUSAN C.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Draft Transition Process Requirements for Part D Sponsors. Medicare Modernization Act: 2007 Draft Guidelines -- Formularies: CMS Strategy for Affordable Access to Comprehensive Drug Coverage. CMS Decision to Require Part D plans to remove prescription niacin from their formularies. CMS-6272-IFC - Medicare Secondary Payer Amendments. CY 2007 Medicare Marketing Guidelines Update. CMS-1270-P - Medicare Program: Competitive Acquisition for Certain Durable Medical Equipment Prosthetics, Orthotics, and Supplies Proposed Rule. Medicare Prescription Drug Benefit Implementation. H.R. 5182: Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2006. S.2654: Pharmacy Access Improvement (PhAlm) Act of 2006. S.2551: Prompt Payment of Health Benefits Claims Act of 2006. S. 1932: The Deficit Reduction Act of 2005 (DRA). S.2563: Pharmacist Access and Recognition in Medicare (PhARM) Act of 2006. S. 2841: Medicare Safe Needle Disposal Coverage Act of 2005. Medicare Coverage of Prescription Level Niacin. Implementation of the Deficit Reduction Act.

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BISHOP, SUSAN K

Covered Official Position (if applicable): N/A

Name: JAMGOCHIAN, HRANT

Covered Official Position (if applicable): N/A

Name: LUNNER, KRISTINA E.

Covered Official Position (if applicable): N/A

Name: WINCKLER, SUSAN C.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

H.R.3199: USA PATRIOT and Terrorism Prevention Reauthorization Act of 2005; Combat Meth Act. H.R. 1808: Safe Online Drug Act of 2005. S. 334: Pharmaceutical Market Access and Drug Safety Act of 2005. 2005N-0354 - Consumer-Directed Promotion of Regulated Medical Products. 2005D-0011 - Draft Guidance for Industry "Labeling for Human Prescription Drug and Biological Products I Implementing the New Content and Format Requirements". 2005P-0411 - Wyeth Citizen Petition: Seeking FDA Actions to counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs that Endanger Public Health. H.R. 5280: Dextromethorphan Distribution Act of 2006. H.R. 4769: Prescription Drug Abuse Elimination Act of 2006. H.R. 1539: A bill to amend the Public Health Service Act with respect to the responsibilities of a pharmacy when a pharmacist employed by the pharmacy refuses to fill a valid prescription for a drug on the basis of religious beliefs or moral convictions, and for other purposes. H.R. 1652: Access to Legal Pharmaceuticals Act. S. 544: Patient Safety and Quality Improvement Act of 2005. S. 809: Access to Legal Pharmaceuticals Act. Pharmacist Compounding. S. 778: Pharmacy Consumer Protection Act of 2005. Counterfeit Drugs. S. 3807: Enhancing Drug Safety and Innovation Act of 2006. H.R. 1815: Financial Services Regulatory Relief Act of 2005. H.R. 5122: National Defense Authorization Act for Fiscal Year 2007; Pharmacy Program. H.R. 5384: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007; Prescription Drug Importation. H.R. 5441: Department of Homeland Security Appropriations Act, 2007; Prescription Drug Importation. Health Information Technology. H.R. 2862: Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2006; Combat Meth Act.

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BISHOP, SUSAN K
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A
Name: WINCKLER, SUSAN C.
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 11, 2006

Printed Name and Title: JASON DE LA PENA - ADMIN ASSISTANT

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 11, 2006

Printed Name and Title: -